Women's preferences for integrating multi-product pre-exposure prophylaxis delivery programs within services for sexually transmitted infections and reproductive health care in Uganda: a discrete choice experiment
Brenda Kamusiime, Patricia M. Smith, Alisaati Nalumansi, Tara E. Wood, George Eram, Vicent Kasiita, Paul Ssendiwala, Agnes Nakyanzi, Felix Bambia, Timothy R. Muwonge, Andrew Mujugira, Elizabeth T. Montgomery, Renee Heffron

TL;DR
Ugandan young women prefer integrating HIV prevention programs with services for STI testing and reproductive health, according to a study using discrete choice experiments.
Contribution
The study identifies specific preferences of adolescent girls and young women for multi-product PrEP delivery programs integrated with reproductive health services.
Findings
Access to additional services like STI testing and family planning had the highest influence on PrEP program choice.
Preferences for services were significantly higher than for stand-alone PrEP programs.
Facility type, information dissemination method, and location proximity had lower influence on preferences.
Abstract
HIV prevention is paramount for adolescent girls and young women (AGYW) in Uganda, and oral pre-exposure prophylaxis (PrEP) is not always a suitable option. With emerging novel HIV prevention products (e.g., ring, injectables), there are opportunities to explore AGYW preferences to inform strategies for integrating PrEP choice into routine care. From January–September 2024, we recruited AGYW aged 16–25 years from community sites in Kampala, Uganda for a cross-sectional discrete choice experiment (DCE) to determine the most preferred attributes and levels of multi-product PrEP programs. The DCE was developed via literature review, informal conversations with AGYW, and cognitive interviewing among AGYW using a prototype instrument. In the final iteration, attributes (and levels) included: method of PrEP information dissemination (WhatsApp, brochure, in-person consultations), PrEP…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2| Characteristic | DCE participants |
|---|---|
| N (%) or Median (IQR) | |
| Age | 21.0 (20–23) |
| Country of birth | |
| Uganda | 288 (96.0%) |
| Other | 12 (4.0%) |
| Highest level of education | |
| Primary school | 85 (28.3%) |
| Secondary school | 157 (52.3%) |
| Technical college or university | 58 (19.3%) |
| Owns a mobile phone | 276 (92.0%) |
| Owns a smartphone | 189 (68.5%) |
| Sexually active | 255 (85.0%) |
| Sexual partner gender preference | |
| Men only | 253 (99.2%) |
| Both men and women | 2 (0.8%) |
| Had vaginal intercourse within the past month | 226 (88.6%) |
| Number of times had sex in the last 30 days | 7 (3–24) |
| Sexual partners in the last 30 days | 3 (1–15) |
| Type of current sexual partners, | |
| Regular partner | 158 (69.9%) |
| Casual partner | 123 (54.4%) |
| Other | 2 (0.9%) |
| Relationship status | |
| Married | 37 (12.3%) |
| Primary partner, but not married | 167 (55.7%) |
| Casual partner | 33 (11.0%) |
| Not in a relationship | 61 (20.3%) |
| Other | 2 (0.7%) |
| Uses condoms some of the time or more frequently | 182 (60.7%) |
| Ever used PrEP | 115 (38.3%) |
| Currently using PrEP | 49 (42.6%) |
| Where PrEP is accessed, among those currently using PrEP | |
| Research study | 12 (24.5%) |
| Private clinic | 2 (4.1%) |
| Government clinic or hospital | 32 (65.3%) |
| Other | 3 (6.1%) |
| Currently using contraception | 217 (72.3%) |
| Ever diagnosed with an STI | 88 (29.3%) |
- —National Institutes of Health10.13039/100000002
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGlobal Maternal and Child Health · HIV/AIDS Research and Interventions · Adolescent Sexual and Reproductive Health
Introduction
The 2025 Global AIDS Update reported a 56% reduction in the number of new HIV acquisitions in eastern and southern Africa (1). However despite the overall decrease, AGYW accounted for 28% of new HIV infections in the region, a disproportionate burden and three-fold increase compared to their male counterparts (2). Daily oral HIV pre-exposure prophylaxis (PrEP) has high efficacy and is an approved prevention strategy (3). Demonstration projects and data from programmatic delivery show high oral PrEP uptake among AGYW in eastern and southern Africa, yet many discontinue by 12 months or earlier, due in large part to a challenging daily dosing schedule. Side effects, frequent refill schedules, negative judgment by healthcare providers, and stigma are also cited as reasons influencing early discontinuation (4). Novel PrEP products, both approved and in roll-out phases regionally and in Uganda, include a 2-monthly injection with cabotegravir and a monthly dapivirine-eluting vaginal ring (5). More recently, a 6-monthly injection with lenacapavir was approved for use for HIV prevention, and other promising long-acting formulations are in development (6–9). The promise of novel PrEP products offers opportunities to understand AGYW experiences with daily oral PrEP and identify new or revamped strategies that meet their preferences and will facilitate upcoming multi-product PrEP programs to achieve high prevention coverage.
Currently in Uganda, oral PrEP is offered at government clinics, hospitals, HIV testing and counselling centers, implementation research and demonstration sites, and not-for-profit organizations (10–12). The dapivirine ring and 2-monthly injectable cabotegravir are included in Uganda HIV prevention clinical guidelines, and limited quantities were distributed in the country during a now-terminated USAID-supported demonstration project at 7 public health facilities (10). To reduce financial and programmatic dependence on foreign assistance, the Uganda Ministry of Health is working to restart delivery of these commodities, donated from multinational organizations. Originally rolled out in a phased manner in Uganda, oral PrEP was first offered to HIV serodifferent couples and later expanded to other key populations including men who have sex with men (MSM), sex workers, people who inject drugs, fisherfolk, transgender populations, adolescent girls and young women, and truck drivers (13). Newly introduced PrEP products could be integrated into existing oral PrEP programs, resulting in multi-product PrEP service delivery models. In line with this, the Uganda Ministry of Health is strongly recommending the integration of PrEP into routine clinical services, with existing clinic staff leading the effort to integrate HIV services within other health services; the goal being to shift away from stand-alone HIV and PrEP programs. To contribute data to inform future PrEP programmatic decision making, we conducted a discrete choice experiment (DCE) among AGYW, including those experienced with oral PrEP and PrEP-naïve.
Materials and methods
We conducted a DCE among AGYW between the ages of 16 and 25 years, a population considered important candidates for PrEP, based on their sexual behaviour. Potential participants were recruited in Kampala, Uganda from PrEP studies previously conducted at the IDI-Kasangati research clinic and through partnerships with family planning centers, vocational training schools, and public clinics where both antiretroviral therapy and PrEP are dispensed. To gain rapport with clinics and schools, the study community liaison officer sensitised clinic/school staff and provided them with information about the study. All potential participants were referred to the study recruitment team and those meeting eligibility criteria were consecutively enrolled. Based on recommendations for discrete choice experiments and the number of attributes and levels in our DCE, a target enrollment goal of 300 participants was set (14, 15).
The study was conducted at Makerere University College of Health Sciences Infectious Diseases Institute's Kasangati clinical research site in Kampala, Uganda, from January to September 2024. Potential participants were invited to the research site and underwent testing for HIV according to national guidelines. Women meeting eligibility criteria who were willing and able to undergo informed consent were enrolled. Eligibility criteria for those ages 16–17 years included qualifying as an emancipated minor, according to Ugandan ethics regulations. On the same day as study screening, eligible AGYW who were willing to participate in the study underwent an informed consent process and completed the interviewer-administered questionnaires to capture their current and recent choices about PrEP use and their sexual behaviour, as well as the choice set questions comprising the DCE.
Prior to study launch, we used a two-step process to develop the DCE, including selecting attributes and defining levels for each attribute. Formative research, including literature reviews and informal interviews with PrEP-experienced AGYW, was used to develop initial attributes and levels. With these lists, we created a prototype of the DCE data collection instrument and then conducted six cognitive interviews where DCE language and pictorial representations of attribute levels were discussed with AGYW. Thorough review by the broader study team was incorporated into a subsequent draft of the attributes, Luganda-translated text, and updated graphics. The participant-facing DCE included attributes and levels described in words and images purchased from image galleries or obtained freely from online sources.
Final attributes for the DCE included: (1) how AGYW would like to have PrEP information shared with them; (2) how PrEP counselling is delivered; (3) location of the PrEP program; (4) type of place where PrEP program is located; (5) whether other services are available at the program site; (6) how long they would be willing to wait to access PrEP and; (7) and the cost associated with the PrEP program. Piloting of the DCE was conducted prior to implementation, and the tool was revised a final time to ensure clarity. The attributes and levels represented in the DCE are shown in Figure 1.
Discrete choice experiment attributes and levels.
DCE procedures
Prior to the DCE, participants engaged in a structured, interviewer-administered survey to obtain basic demographics, relationship status, current sexual behaviour, PrEP experience, and HIV risk factors. Following the survey, a paper-based practice DCE was introduced to each participant, which consisted of two opportunities to choose their preference for local food provision. These data were used solely to familiarise participants with the DCE process and were not analysed*.* Subsequently, the DCE was administered on a password protected electronic tablet in Luganda (local language) and English. Two female and two male trained research assistants were available to administer the DCE or to assist participants in self-completing the DCE based on their preference and comfort level with the tablet.
Each participant responded to nine hypothetical PrEP program choice sets, which asked her to choose between two different PrEP program scenarios. We excluded an option to choose “neither” of the PrEP program scenarios presented. To create a full set of hypothetical scenarios, a fractional factorial choice matrix was constructed for seven attributes, each with 2–3 levels. A D-efficient non-orthogonal design was used to generate the choice matrix, aiming to maximize statistical efficiency. Choice sets were then randomly assigned using the balanced overlap method. The DCE was designed and administered using Sawtooth Software Lighthouse Studio 9.15.0 (Provo, UT, USA). All data were quality-checked weekly to ensure data completeness.
Ethics
All participants provided written informed consent in English or Luganda. Participants ages 16–17 years were considered emancipated minors and provided written consent. The study protocol received ethical approval from the University of Alabama at Birmingham Institutional Review Board (IRB-300011438), Infectious Diseases Institute Research Ethics Committee (IDI-REC-2023-61) and the Uganda National Council for Science and Technology (HS3665ES).
Statistical methods
Summary statistics were calculated to describe participant sociodemographic characteristics and PrEP experience. Responses to the discrete choice experiment were analysed using multinomial logit modeling. Sub-group analyses were performed using stratified modelling for participants with a) any previous PrEP use or no previous PrEP use and b) less than three partners in the prior 30 days or more than three partners in the prior 30 days. Importance scores and preference weights were reported. All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and Sawtooth Software Lighthouse Studio 9.15.0.
Results
Of the 376 screened participants, 300 AGYW met the eligibility criteria, provided consent, and completed the DCE. All 76 AGYW who screened out were ineligible due to age. The median age was 21 years [interquartile range (IQR): 20–23]. Mobile phone ownership was very common (92%), including 68.5% who owned a smartphone (Table 1). Among AGYW, 85% reported being sexually active, and the median number of partners in the past 30 days was 3 (IQR: 1–15). Additionally, 29% of AGYW reported ever being diagnosed with a sexually transmitted infection (STI). A total of 38.3% of participants reported having ever used oral PrEP; of those, 42.6% (16.3% of total cohort) were currently using PrEP at the time of the DCE.
The “access to other services” attribute exerted the most influence on PrEP program choice (importance score: 27.0%) (Figure 2). Participants had a strong preference for STI testing services [preference weight [PW]: 0.39, 95% confidence interval [CI]: 0.32, 0.47] and a moderate preference for family planning services (PW: 0.14, 95% CI: 0.07, 0.21). The “cost of program” attribute was the second most influential program attribute (importance score, 18.2%) with participants preferring no cost (PW: 0.31, 95% CI: 0.26, 0.36) vs. paying a small cost for PrEP (PW: −0.31, 95% CI: −0.36, −0.26).
Overall DCE results for each attribute and level.
Other attributes had lower importance and were not very influential on choice, including “wait time” (importance score: 15.8%), “getting PrEP” (referring to how PrEP counselling is delivered) (importance score: 12.3%), “type of place where the PrEP program is offered” (importance score: 9.7%), method of “PrEP information sharing” (10.2%), and “location of PrEP program” (denoting nearness of the program to home, work or school) (6.9%). In subgroup analyses, attribute importance and preferences were similar for a) PrEP-experienced and PrEP-naïve participants and b) participants with fewer than three and three or more partners in the past 30 days.
Discussion
The findings from this DCE among 300 Ugandan AGYW highlight the importance of bundling PrEP delivery alongside other salient health services, such as family planning and STI treatment, with lesser emphasis on factors such as mode of counselling and proximity to services. In this study, 85% of AGYW reported being sexually active, and participants' strong preference for STI testing services suggests that they view these services as a critical component of their overall sexual and reproductive health needs. This is especially important in Uganda, where access to regular STI testing is still limited (16), showing a gap between the services available and what AGYW need. Numerous studies, including systematic reviews, have documented a high prevalence of STIs among AGYW in sub-Saharan Africa, highlighting the need to integrate STI prevention into broader HIV prevention strategies (17).
Additionally, the preference for integrating PrEP with family planning services among AGYW in our DCE suggests that PrEP programs designed to include broader reproductive health support may enhance PrEP acceptability and uptake, aligning with research that supports the view that offering PrEP alongside other essential health services improves both uptake and retention (18). This is consistent with the Uganda Ministry of Health's current plan to integrate reproductive health services at public health clinics and move away from stand-alone HIV/PrEP services with dedicated staffing. The goal is to create a more unified and sustainable health system by integrating PrEP into routine service delivery (19). As Uganda launches delivery of injectable PrEP (cabotegravir recently became available and lenacapavir is anticipated to become available in 2026), there is an opportunity to integrate PrEP with family planning and streamline clinic visits by aligning dosing schedules and other delivery components (e.g., providing injections for family planning and PrEP on the same day when possible). In addition, novel products, such as the dual prevention pill, may be perfectly suited to this population group since it provides oral family planning and PrEP in one pill and multiple months of pills can be provided at once (20, 21).
Cost emerged as the second most influential DCE attribute, with participants expressing a clear preference for free PrEP services. This finding aligns with literature demonstrating that financial barriers significantly impact healthcare access, particularly for young people from resource-limited settings (22). A recent review of PrEP uptake among AGYW in Eastern, Southern, and Western Africa identified cost as a significant barrier deterring AGYW in sub-Saharan Africa from accessing PrEP (23). Recent shifts in international donor funding priorities and the introduction of more expensive PrEP products have raised concerns about the sustainability of free PrEP for AGYW in sub-Saharan Africa (24), and national-level directives have called for formerly dedicated PrEP services to be integrated with other clinic services in Uganda. As such, future programs will need to keep costs low to initiate PrEP use and support uptake. Encouragingly, our DCE finding that bundling PrEP with other health services could improve uptake and retention offers support for the Uganda Ministry of Health's recent directive to integrate PrEP into routine clinic services (19, 25). With the dramatic reduction in USAID funding and subsequent reduction of HIV prevention and treatment staff, the Ministry aims to alter the situation with parallel systems of HIV-specific vs. general health services (26). This integrated approach not only reflects health system realities but also aligns with the preferences of AGYW as supported by our DCE results.
While attributes such as wait time, service location, and information-sharing methods were ranked as lower priorities in this DCE, they nonetheless play a meaningful role in shaping the accessibility and acceptability of PrEP services among AGYW. Prior research supports that long wait times at health facilities can discourage young women from initiating or continuing PrEP (27). Similarly, the physical location of services, whether in youth-friendly clinics, community-based sites, or through mobile outreach, can significantly impact uptake by influencing convenience, perceived privacy, and safety (28). These findings show that even less prioritized service features should be important considerations when designing PrEP delivery models that meet the needs of AGYW. Programs can choose to adapt delivery approaches that work best for specific contexts and the preferences of AGYW as long as the PrEP services are bundled with other essential health services (29).
The relatively lower importance placed on being close to a clinic offering PrEP suggests that AGYW might be open to traveling for PrEP access if the service provision is satisfactory, such as being able to access adjacent health services or experiencing shorter wait times. However, this finding may reflect the setting, as the young women in this study live in an area with more health services and easier transport than many other parts of the country. A qualitative study in Kenya explored young women's experiences accessing PrEP at the same pharmacies where they obtained contraception. Participants disclosed that spending less time at the pharmacy encouraged them to return for refills, unlike at health facilities where long wait times were discouraged, ultimately impacting PrEP adherence (30). Additionally, pharmacies may consider delivery options for PrEP products that do not need clinician delivery (e.g., oral products) as they provide faster and more discrete services (31).
The similarity in attribute preferences between PrEP-experienced and PrEP-naïve participants suggests that programs can benefit both groups equally. The consistency of preferences across participants with different levels of sexual activity indicates that targeted PrEP promotion strategies may not need to vary significantly based on number of sexual partners or whether clients are engaged in transactional sex. Our DCE results suggest that one streamlined PrEP-offer approach can meet the needs of many young women, regardless of their background or experiences, resulting in establishing cost-efficient programs in locations where funding and staff are limited.
The strengths of our study include the inclusion of a large number of AGYW who were recruited from a diverse set of service organizations and research programs and our methods that incorporated DCE practice questions and opportunity for participants to become acquainted with the question format before responding. We were, however, limited in the number of attributes and levels that we could include in the DCE as we wanted to reduce the amount of time for participant engagement and maintain high study rigor. Another limitation is that our DCE excluded an option for participants to tell us that “neither option” would be preferable to the ones offered, providing us with clear data on preferences but no data on absolute preferences. Since our participants were from the Kampala, Uganda area, an urban setting, and seeking health care, results may not be generalizable to other settings, and the cross-sectional nature of the DCE provides information only about this moment in time.
Conclusions
In this DCE, we found a strong preference for PrEP delivery to be integrated within family planning, reproductive health services and STI testing/treatment services. The provision of PrEP as free-of-charge also influenced participants' choice for PrEP programming, suggesting the need for comprehensive, affordable, multi-service healthcare models. Ensuring that PrEP is provided at no cost will not only support initiation but encourage sustained use—both key factors as AGYW experience dynamic degrees of HIV risk and navigate stigma associated with accessing sexual and reproductive health services. While factors such as wait times and service location were less influential, addressing these considerations has the potential to improve overall user experience and retention. As PrEP programs strive to include new products, including injectable cabotegravir and lenacapavir, it is crucial to use insights from AGYW to shape sexual and reproductive health services that meet their needs and support both PrEP initiation and retention and that we leverage implementation science research opportunities to test different delivery strategies. At the same time, new PrEP products are being rolled out amid significant shifts in global funding and policy landscape. How PrEP is delivered in Uganda is now part of a tidal shift from stand-alone HIV and PrEP services toward full integration into routine care. Presenting and interpreting these DCE findings among this monumental transformation is vital for the future of PrEP use and the programs that support sustainability and uptake.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1UNAIDS. AIDS, crisis and the power to transform: UNAIDS Global AIDS Update 2025. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) (2025).
- 2The Urgency of Now. AIDS at a Crossroad. Joint United Nations Programme on HIV/AIDS. Geneva: United Nations (2024).
- 3Centers for Disease Control. Preventing HIV with Pr EP: United States Centers for Disease Control. Available online at: https://www.cdc.gov/hiv/prevention/prep.html (Accessed November 01, 2024).
- 4Celum C Hosek S Tsholwana M Kassim S Mukaka S Dye BJ Pr EP uptake, persistence, adherence, and effect of retrospective drug level feedback on Pr EP adherence among young women in Southern Africa: results from HPTN 082, a randomized controlled trial. P Lo S Med. (2021) 18(6):e 1003670. 10.1371/journal.pmed.100367034143779 PMC 8253429 · doi ↗ · pubmed ↗
- 5Celum CL Bukusi EA Bekker LG Delany-Moretlwe S Kidoguchi L Omollo V Pr EP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. (2022) 25(7):e 25962. 10.1002/jia 2.2596235822945 PMC 9278271 · doi ↗ · pubmed ↗
- 6World Health Organization. Guidelines on Lenacapavir for HIV Prevention and Testing Strategies for Long-acting injectable pre- Exposure Prophylaxis (Pr EP). Geneva: World Health Organization (WHO) (2025).40743386 · pubmed ↗
- 7Bekker LG Das M Abdool Karim Q Ahmed K Batting J Brumskine W Twice-Yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. (2024) 391(13):1179–92. 10.1056/NEJ Moa 240700139046157 · doi ↗ · pubmed ↗
- 8Gillespie G Carstens RP Zang X Vargo R Kapoor Y Bhattacharyya A Safety and pharmacokinetics of MK-8527, a novel n RTTI in adults without HIV. In: Game Changers in Prevention of HIV and Sexually Transmitted Infections. Conference on Retroviruses and Opportunistic Infections (CROI); 2024 Mar 3–6; Denver, CO. San Francisco, CA: CROI Foundation/IAS-USA (2024). Available online at: https://www.croiwebcasts.org/s/2024 croi/Oral Session-04
